ONCOS-102 (Ad5/3-D24-GMCSF) with triple orphan status for mesothelioma, soft tissue sarcoma and ovarian cancer in the U.S. and Europe showed evidence of immune priming on biopsies in Phase I clinical trials [101] (discussed below). Here, CSF2 is linked to soft tissue sarcoma.